EGATEN
- Product NDC
- 0078-0937
- 11-digit product format
- 000780937
- Labeler code
- 0078
- Product ID
- 0078-0937_59dff6dc-c0b0-4f26-9738-32f8a6540033
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- triclabendazole
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Novartis Pharmaceuticals Corporation
- Application
- NDA208711
- Marketing category
- NDA
- Marketing start
- 2019-02-13
- Substance
- TRICLABENDAZOLE
- Active strength
- 250 mg/1
- Pharmacologic classes
- Anthelmintic [EPC], Anthelmintics [CS], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2A6 Inhibitors [MoA], Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- EGATEN
- Listing expiration
- 2027-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| TRICLABENDAZOLE | 250 mg/1 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 0078-0937-91 | EGATEN | 4 in 1 BLISTER PACK | TABLET | 4 | | 11 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 0078-0937 | EGATEN (TRICLABENDAZOLE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | 11 | Current NDC, Legacy NDC, 1 package rows | 20250308_5552884e-10ea-450c-9658-d3d4f33c946e.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 0078-0937-91 | 00078093791 | 4 TABLET in 1 BLISTER PACK (0078-0937-91) | 4 tablet | 2019-02-13 | 0000-00-00 | No | No | Current |